



ASX ANNOUNCEMENT

27 November 2024

Opyl Secures Loan From Antanas Guoga Irwin Biotech and Maryton Australia

Melbourne, Australia – Opyl Limited (ASX: OPL or "the Company") is delighted to announce the execution of three loan agreements, highlighting the commitment and belief of our long-term supporters in the transformative potential of our AI-powered clinical trial optimisation platform, TrialKey.

The agreements bring in a total of \$305,000 AUD from Antanas "Tony" Guoga, Irwin Biotech Nominees Pty Ltd ("**Irwin Biotech**") and Maryton Australia Pty Ltd ("**Maryton Australia**"), all who have demonstrated unwavering confidence in Opyl's strategic vision. These loans bolster Opyl's financial position, ensuring we are well-equipped to scale TrialKey, a critical component in enhancing clinical trial efficiency.

Key Highlights

- Loan from Tony Guoga*
 - Loan Amount: \$150,000 AUD
 - Repayment: 31 December 2025
 - Interest: 1.5% per month, payable quarterly
 - Convertible to fully paid shares at \$0.015 per share
 - Includes one free attaching option per share (exercise price: \$0.015, maturity: 3 years)
- Loan from Irwin Biotech*
 - Loan Amount: \$75,000 AUD
 - Repayment: 31 December 2025
 - Interest: 1.5% per month, payable quarterly
 - Convertible to fully paid shares at \$0.015 per share
 - Includes one free attaching option per share (exercise price: \$0.015, maturity: 3 years)



- Loan from Maryton Australia*
 - Loan Amount: \$80,000 AUD
 - Repayment: 31 December 2025
 - Interest: 1.5% per month, payable quarterly
 - Convertible to fully paid shares at \$0.015 per share
 - Includes one free attaching option per share (exercise price: \$0.015, maturity: 3 years)

*All are subject to shareholder approval for conversion terms at the next Extraordinary General Meeting ("**EGM**").

Backing from Proven Investors

Tony Guoga, also known as "Tony G," is a globally respected entrepreneur, investor, and strategist with an impressive history of supporting high-potential ventures. His recent success with NoviqTech, a blockchain-focused company whose share value tripled within months, demonstrates his ability to identify and elevate emerging opportunities. Tony has publicly cited the strength of technology and team as critical factors in his decision-making process.

Tony's decision to support Opyl reflects the same level of conviction. Known for his selective and strategic approach to investments in the Australian market, his involvement is a strong endorsement of TrialKey's capacity to revolutionise clinical trial recruitment. His reputation and foresight significantly bolster Opyl's credibility and growth trajectory.

Equally important is Irwin Biotech and Maryton Australia, whose support has been instrumental to Opyl's development. Irwin Biotech and Maryton Australia's enduring belief in the company's vision highlights the strong relationships Opyl has cultivated with its stakeholders. Their steadfast backing adds a layer of trust and reliability that enhances Opyl's position in the market.

Together, this investor support provides not just financial resources but also the strategic credibility necessary to propel Opyl towards achieving its ambitious goals.



Executive Commentary

Saurabh Jain, Executive Chairman of Opyl, remarked:

"The steadfast support has been instrumental in shaping Opyl's growth trajectory. Their decision to back Opyl validates our vision, product, and growth potential. This funding will enable us to continue innovating, improving TrialKey, and delivering outstanding value to stakeholders."

A director of Irwin Biotech, commented:

"Our investment in Opyl reflects our strong confidence in its transformative potential to revolutionise the clinical trial landscape. Leveraging advanced AI technology, Opyl is tackling critical industry challenges and setting a new standard for more efficient, effective, and impactful clinical research. We are proud to support a company at the forefront of such meaningful innovation."

Antanas "Tony" Guoga added:

"I've built my investment career by backing technologies and teams that have the potential to create transformative impact, and Opyl is no exception. TrialKey addresses one of the most significant bottlenecks in the healthcare and research sectors—patient recruitment for clinical trials. With its innovative AI-powered approach, Opyl is uniquely positioned to lead the way in this space. Similar to my recent investment in NoviqTech, where we are already seeing impressive results, I believe Opyl's potential for growth and value creation is enormous. I'm excited to be part of this journey and to help the company scale its impact globally."

Performance Securities Terms

Opyl Limited and Dr. Megha Jain Pty Ltd (Saurabh Jain as Supplier Principal and interim CEO) have entered into a consultancy agreement in November 2023. For a summary of the terms and conditions of this agreement please see ASX announcement dated 24 November 2023.

Subject to shareholder approval at a future general meeting to be called by the Company, the Board has agreed to amend the terms of the performance securities in relation to the agreement as follows:



- **Tranche 2:** \$50,000 for a successful product launch by Opyl Limited (the Customer) achieving \$100,000 in direct TrialKey product sales.
 - Price per performance security set at **\$0.015**.
- **Tranche 3:** \$100,000 for successful attraction and recruitment of a CEO or CRO.
 - Price per performance security also set at **\$0.015**.

All other terms of the agreement remain unchanged.

Please also see Resolution 5 of the notice of annual general meeting released to the ASX on 30 October 2024. Mr Saurabh Jain is subject to shareholder approval, intending to be issued equity in lieu of his salary for 1 July 2024 to 1 July 2025.

This announcement has been authorised for release by the board

-ENDS-

For investor enquiries:

Bernice Averion
Head of Marketing and Communications
Phone: +61 415 311 957
Email: bernice@trialkey.ai

About Opyl Limited (ASX: OPL)

Opyl Limited is an AI company dedicated to leveraging data and technology to transform the landscape of clinical trials and medical research. With a commitment to innovation and strategic growth, Opyl is positioned to lead the way in shaping the future of healthcare solutions.